- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06338358
Understanding Participation Habits Among Plaque Psoriasis Patients
In the Patient's Words: Understanding Patient Participation and Engagement in Plaque Psoriasis Clinical Trials
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.
The data collected from this study will help improve future outcomes for all plaque psoriasis as well as those in under-represented demographic groups.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michael B Gill
- Phone Number: (415) 900-4227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
Contact:
- Michael B Gill
- Phone Number: 415-900-4227
- Email: https://www.withpower.com/contact-us@withpower.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with plaque psoriasis
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.
Exclusion Criteria:
- Refusal of consent
- Women of childbearing potential without a negative pregnancy test; or women who are lactating.
- Any serious and/or unstable pre-existing medical disorders
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of patients who decide to enroll in a plaque psoriasis clinical research.
Time Frame: 3 months
|
3 months
|
|
Number of plaque psoriasis study participants who remain in clinical study until completion.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
General Publications
- Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaci D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9.
- Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020 Mar 1;156(3):258-269. doi: 10.1001/jamadermatol.2019.4029.
- Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 44519568
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plaque Psoriasis
-
Usynova Pharmaceuticals Ltd.RecruitingPlaque Psoriasis | Moderate to Severe Plaque PsoriasisChina
-
Qilu Pharmaceutical Co., Ltd.Recruiting
-
Xiangya Hospital of Central South UniversityNot yet recruiting
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.MC2 TherapeuticsRecruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.Recruiting
-
Haisco Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Sun Pharmaceutical Industries, Inc.CompletedPlaque PsoriasisUnited States
-
Oruka Therapeutics, Inc.RecruitingPlaque PsoriasisUnited States, Canada
-
Oruka Therapeutics, Inc.RecruitingPlaque PsoriasisUnited States, Canada
-
InventisBio Co., LtdRecruiting